ES2823127T3 - Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4 - Google Patents
Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4 Download PDFInfo
- Publication number
- ES2823127T3 ES2823127T3 ES17742926T ES17742926T ES2823127T3 ES 2823127 T3 ES2823127 T3 ES 2823127T3 ES 17742926 T ES17742926 T ES 17742926T ES 17742926 T ES17742926 T ES 17742926T ES 2823127 T3 ES2823127 T3 ES 2823127T3
- Authority
- ES
- Spain
- Prior art keywords
- ethyl
- thiazol
- ethoxy
- benzo
- dioxino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 191
- 101001113471 Homo sapiens Proteinase-activated receptor 4 Proteins 0.000 title description 56
- 102100023710 Proteinase-activated receptor 4 Human genes 0.000 title description 56
- 101000613565 Homo sapiens PRKC apoptosis WT1 regulator protein Proteins 0.000 title description 52
- 239000003112 inhibitor Substances 0.000 title description 13
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title description 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title description 2
- -1 -S (O) 2NRaRa Chemical group 0.000 claims abstract description 796
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 222
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 56
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 55
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 48
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 42
- 125000003709 fluoroalkyl group Chemical group 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 39
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 39
- 125000001424 substituent group Chemical group 0.000 claims abstract description 37
- 239000012453 solvate Substances 0.000 claims abstract description 29
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims abstract description 28
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract description 28
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 25
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 25
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 23
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 21
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract description 21
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 19
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 19
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract description 19
- 125000003118 aryl group Chemical group 0.000 claims abstract description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 18
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 18
- 125000002098 pyridazinyl group Chemical group 0.000 claims abstract description 18
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 16
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims abstract description 16
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims abstract description 16
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 16
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 claims abstract description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 11
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims abstract description 10
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims abstract description 10
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims abstract description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 9
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims abstract description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 9
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims abstract description 9
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims abstract description 8
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims abstract description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 7
- 239000001301 oxygen Substances 0.000 claims abstract description 7
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims abstract description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract description 4
- 125000002541 furyl group Chemical group 0.000 claims abstract description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims abstract description 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims abstract description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims abstract description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 230
- 238000000034 method Methods 0.000 claims description 189
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 176
- 235000013350 formula milk Nutrition 0.000 claims description 83
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 239000000460 chlorine Substances 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- 208000035475 disorder Diseases 0.000 claims description 42
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 41
- 230000009424 thromboembolic effect Effects 0.000 claims description 38
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 31
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 30
- 208000007536 Thrombosis Diseases 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 15
- 206010047249 Venous thrombosis Diseases 0.000 claims description 14
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 claims description 14
- 125000005605 benzo group Chemical group 0.000 claims description 13
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 11
- 201000001320 Atherosclerosis Diseases 0.000 claims description 11
- 208000006011 Stroke Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 229920006358 Fluon Polymers 0.000 claims description 9
- RTLYCOOENXHEGT-UHFFFAOYSA-N [2-(2-hydroxyethoxy)pyrimidin-5-yl] carbamate Chemical compound C(N)(OC=1C=NC(=NC=1)OCCO)=O RTLYCOOENXHEGT-UHFFFAOYSA-N 0.000 claims description 9
- 239000007943 implant Substances 0.000 claims description 8
- OKGVGUUEFJXBGT-UHFFFAOYSA-N (3-cyanophenyl) carbamate Chemical compound NC(=O)Oc1cccc(c1)C#N OKGVGUUEFJXBGT-UHFFFAOYSA-N 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 206010002388 Angina unstable Diseases 0.000 claims description 5
- 206010008088 Cerebral artery embolism Diseases 0.000 claims description 5
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims description 5
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims description 5
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 5
- 206010063544 Renal embolism Diseases 0.000 claims description 5
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 5
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 5
- 208000002528 coronary thrombosis Diseases 0.000 claims description 5
- 201000010849 intracranial embolism Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 201000005060 thrombophlebitis Diseases 0.000 claims description 5
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 5
- DOHQSYULTPMCOG-UHFFFAOYSA-N (6-cyanopyridin-3-yl) carbamate Chemical compound NC(=O)OC1=CC=C(C#N)N=C1 DOHQSYULTPMCOG-UHFFFAOYSA-N 0.000 claims description 4
- BYWHPNJRQASNFX-ZDUSSCGKSA-N 1-cyclopropyl-3-[[(7S)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methyl]urea Chemical compound C1(CC1)NC(=O)NC[C@H]1OC2=C(C1)C1=C(N=C(S1)C1=C3N=CC(=NC3=CC(=C1)C)OC)C=C2F BYWHPNJRQASNFX-ZDUSSCGKSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- VOYIQZJXBICUOX-NSHDSACASA-N [(7S)-2-(2-ethoxy-7-methylquinoxalin-5-yl)-5-fluoro-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound C(C)OC1=NC2=CC(=CC(=C2N=C1)C=1SC2=C(N=1)C=C(C1=C2C[C@H](O1)CO)F)C VOYIQZJXBICUOX-NSHDSACASA-N 0.000 claims description 4
- INLUMHLYFJRCGX-UHFFFAOYSA-N [2-(2-methoxy-7-methylquinoxalin-5-yl)-8-methyl-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound COC1=NC2=CC(=CC(=C2N=C1)C=1SC2=C(N=1)C=CC1=C2C(C(O1)CO)C)C INLUMHLYFJRCGX-UHFFFAOYSA-N 0.000 claims description 4
- YVTYOJPYNLAXHP-UHFFFAOYSA-N [2-[2-(difluoromethoxy)-7-methylquinoxalin-5-yl]-4-fluoro-7,8-dihydro-[1,4]dioxino[2,3-g][1,3]benzothiazol-8-yl]methanol Chemical compound FC(OC1=NC2=CC(=CC(=C2N=C1)C=1SC2=C(N=1)C(=CC1=C2OC(CO1)CO)F)C)F YVTYOJPYNLAXHP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000006393 methylpyrimidinyl group Chemical group 0.000 claims description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 claims description 4
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 claims description 4
- APJYETRMZMJYLZ-RFAUZJTJSA-N 8-[(7S,8S)-5-fluoro-7-(hydroxymethyl)-8-methyl-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-2-yl]-3-methoxyquinoxaline-6-carbonitrile Chemical compound FC1=CC=2N=C(SC=2C=2[C@@H]([C@H](OC=21)CO)C)C=1C=C(C=C2N=C(C=NC=12)OC)C#N APJYETRMZMJYLZ-RFAUZJTJSA-N 0.000 claims description 3
- 241000534944 Thia Species 0.000 claims description 3
- FGZXSIJJADHBRO-UHFFFAOYSA-N [6-(dimethylamino)pyridin-3-yl] carbamate Chemical compound C(N)(OC=1C=NC(=CC=1)N(C)C)=O FGZXSIJJADHBRO-UHFFFAOYSA-N 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- DXGPLGPVXNBIQZ-UHFFFAOYSA-L copper;2-hydroxybenzoate;methyl n-(1h-benzimidazol-2-yl)carbamate;6-methyl-n-phenyl-2,3-dihydro-1,4-oxathiine-5-carboxamide;quinolin-8-olate Chemical compound [Cu+2].OC1=CC=CC=C1C([O-])=O.C1=CN=C2C([O-])=CC=CC2=C1.C1=CC=C2NC(NC(=O)OC)=NC2=C1.S1CCOC(C)=C1C(=O)NC1=CC=CC=C1 DXGPLGPVXNBIQZ-UHFFFAOYSA-L 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims description 3
- 238000011324 primary prophylaxis Methods 0.000 claims description 3
- HBJCINXCGUYMGB-UHFFFAOYSA-N (2-phenylpyridin-4-yl) carbamate Chemical compound NC(OC1=CC(C2=CC=CC=C2)=NC=C1)=O HBJCINXCGUYMGB-UHFFFAOYSA-N 0.000 claims description 2
- CYKFBZKEZZXXPP-UHFFFAOYSA-N 2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazole-7-carboxylic acid Chemical compound COc1cnc2c(cc(C)cc2n1)-c1nc2ccc3OC(Cc3c2s1)C(O)=O CYKFBZKEZZXXPP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 230000003836 peripheral circulation Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- KXSIUJJLRBAPGB-UHFFFAOYSA-N 2-ethylquinoxaline Chemical compound C1=CC=CC2=NC(CC)=CN=C21 KXSIUJJLRBAPGB-UHFFFAOYSA-N 0.000 claims 12
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- MJIPSRRYLBPEGR-UHFFFAOYSA-N C1CC2=C(O1)C=CC=1N=C(SC2=1)CC Chemical compound C1CC2=C(O1)C=CC=1N=C(SC2=1)CC MJIPSRRYLBPEGR-UHFFFAOYSA-N 0.000 claims 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 4
- BZWGPEOBQUNEDP-UHFFFAOYSA-N (5-fluoropyridin-3-yl) carbamate Chemical compound C(N)(OC=1C=NC=C(C=1)F)=O BZWGPEOBQUNEDP-UHFFFAOYSA-N 0.000 claims 3
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 3
- 101100021281 Caenorhabditis elegans lin-8 gene Proteins 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 3
- RUOJLMWDYMDFTL-INIZCTEOSA-N 1-[[(7S)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methyl]-3-phenylurea Chemical compound FC1=CC=2N=C(SC=2C=2C[C@H](OC=21)CNC(=O)NC1=CC=CC=C1)C1=C2N=CC(=NC2=CC(=C1)C)OC RUOJLMWDYMDFTL-INIZCTEOSA-N 0.000 claims 2
- UQSIEHVSHVIAPB-UHFFFAOYSA-N [1-(trifluoromethyl)cyclobutyl]methanol Chemical compound OCC1(C(F)(F)F)CCC1 UQSIEHVSHVIAPB-UHFFFAOYSA-N 0.000 claims 2
- YYWSKSKIJXVNTH-UHFFFAOYSA-N [1-(trifluoromethyl)cyclopropyl]methanol Chemical compound OCC1(C(F)(F)F)CC1 YYWSKSKIJXVNTH-UHFFFAOYSA-N 0.000 claims 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 2
- AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 claims 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 claims 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 239000004258 Ethoxyquin Substances 0.000 claims 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 claims 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 claims 1
- 229940093500 ethoxyquin Drugs 0.000 claims 1
- 235000019285 ethoxyquin Nutrition 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 claims 1
- WDZVYHXDNNXLFP-UHFFFAOYSA-N pyridin-3-yl carbamate Chemical compound NC(=O)OC1=CC=CN=C1 WDZVYHXDNNXLFP-UHFFFAOYSA-N 0.000 claims 1
- YPTJZFKTXNUWIN-UHFFFAOYSA-N pyridin-3-yl hydrogen carbonate Chemical compound OC(=O)OC1=CC=CN=C1 YPTJZFKTXNUWIN-UHFFFAOYSA-N 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract description 19
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract description 10
- 125000005348 fluorocycloalkyl group Chemical group 0.000 abstract description 8
- 125000002971 oxazolyl group Chemical group 0.000 abstract description 8
- 125000004103 aminoalkyl group Chemical group 0.000 abstract description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract description 3
- 101150017724 Crhr1 gene Proteins 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 366
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 269
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 182
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 154
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 136
- 235000019439 ethyl acetate Nutrition 0.000 description 133
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 124
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 117
- 239000000203 mixture Substances 0.000 description 115
- 239000007787 solid Substances 0.000 description 98
- 239000011541 reaction mixture Substances 0.000 description 88
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- 238000005160 1H NMR spectroscopy Methods 0.000 description 77
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 76
- 239000002904 solvent Substances 0.000 description 76
- 239000012267 brine Substances 0.000 description 75
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 75
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 71
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 58
- 238000006243 chemical reaction Methods 0.000 description 50
- 239000012044 organic layer Substances 0.000 description 48
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 46
- 229910052938 sodium sulfate Inorganic materials 0.000 description 46
- 235000011152 sodium sulphate Nutrition 0.000 description 46
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 44
- 238000003756 stirring Methods 0.000 description 39
- 239000000741 silica gel Substances 0.000 description 36
- 229910002027 silica gel Inorganic materials 0.000 description 36
- 239000000243 solution Substances 0.000 description 36
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 33
- 239000012043 crude product Substances 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 238000001704 evaporation Methods 0.000 description 28
- 230000008020 evaporation Effects 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 238000004128 high performance liquid chromatography Methods 0.000 description 23
- 238000003556 assay Methods 0.000 description 21
- 229910052796 boron Inorganic materials 0.000 description 21
- 238000003818 flash chromatography Methods 0.000 description 21
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 239000000556 agonist Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 20
- 238000000746 purification Methods 0.000 description 20
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 description 19
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 description 19
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 19
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 19
- 108090000190 Thrombin Proteins 0.000 description 19
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 239000012071 phase Substances 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 238000004809 thin layer chromatography Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 229940123645 Protease-activated receptor-4 antagonist Drugs 0.000 description 11
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 11
- 230000010118 platelet activation Effects 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 10
- 238000004220 aggregation Methods 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 10
- 239000002198 insoluble material Substances 0.000 description 10
- 235000011056 potassium acetate Nutrition 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 239000013058 crude material Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 238000000825 ultraviolet detection Methods 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- 238000004293 19F NMR spectroscopy Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- 229940126629 PAR4 antagonist Drugs 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- LOGAFLFGWNBIIG-UHFFFAOYSA-N pyridin-3-ylcarbamic acid Chemical compound OC(=O)NC1=CC=CN=C1 LOGAFLFGWNBIIG-UHFFFAOYSA-N 0.000 description 8
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 8
- VULJVZXXUQIUEM-OZDPOCAXSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s)-1-[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]hexanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 VULJVZXXUQIUEM-OZDPOCAXSA-N 0.000 description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 239000005695 Ammonium acetate Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 108010079670 alanyl-tyrosyl-prolyl-glycyl-lysyl-phenylalanine Proteins 0.000 description 7
- 235000019257 ammonium acetate Nutrition 0.000 description 7
- 229940043376 ammonium acetate Drugs 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 230000005587 bubbling Effects 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- HAGOWCONESKMDW-FRSCJGFNSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 HAGOWCONESKMDW-FRSCJGFNSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 229940127218 antiplatelet drug Drugs 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- LEPLZGXJTSXTQG-UHFFFAOYSA-N (2-methylpyridin-4-yl) carbamate Chemical compound CC1=CC(OC(N)=O)=CC=N1 LEPLZGXJTSXTQG-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 229910002666 PdCl2 Inorganic materials 0.000 description 5
- 108010000499 Thromboplastin Proteins 0.000 description 5
- 102000002262 Thromboplastin Human genes 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 5
- KTLFENNEPHBKJD-UHFFFAOYSA-K benzyl(trimethyl)azanium;tribromide Chemical compound [Br-].[Br-].[Br-].C[N+](C)(C)CC1=CC=CC=C1.C[N+](C)(C)CC1=CC=CC=C1.C[N+](C)(C)CC1=CC=CC=C1 KTLFENNEPHBKJD-UHFFFAOYSA-K 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 150000002118 epoxides Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000003055 low molecular weight heparin Substances 0.000 description 5
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- AWSUXLKFJUIGEI-UHFFFAOYSA-N (6-methylpyridin-3-yl) carbamate Chemical compound CC1=CC=C(OC(N)=O)C=N1 AWSUXLKFJUIGEI-UHFFFAOYSA-N 0.000 description 4
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 4
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010014513 Embolism arterial Diseases 0.000 description 4
- 101001098557 Homo sapiens Proteinase-activated receptor 3 Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 4
- 102100037133 Proteinase-activated receptor 3 Human genes 0.000 description 4
- 206010037379 Pulmonary embolism and thrombosis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000007814 Unstable Angina Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- LPROLPQTWKDPNU-UHFFFAOYSA-N ethyl 4-(1-benzylindazol-3-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1 LPROLPQTWKDPNU-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 4
- 229940127215 low-molecular weight heparin Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- LCWOVPKDGRAZIW-UHFFFAOYSA-N (2-methylpyrimidin-5-yl) carbamate Chemical compound CC1=NC=C(OC(N)=O)C=N1 LCWOVPKDGRAZIW-UHFFFAOYSA-N 0.000 description 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 206010014522 Embolism venous Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101001135199 Homo sapiens Partitioning defective 3 homolog Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 102100032341 PCNA-interacting partner Human genes 0.000 description 3
- 101710196737 PCNA-interacting partner Proteins 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 102000002020 Protease-activated receptors Human genes 0.000 description 3
- 108050009310 Protease-activated receptors Proteins 0.000 description 3
- KYEGETJTJSPZDT-UHFFFAOYSA-N [6-(3-methyl-1,2,4-triazol-1-yl)pyridin-3-yl] carbamate Chemical compound CC1=NN(C=N1)C1=CC=C(OC(N)=O)C=N1 KYEGETJTJSPZDT-UHFFFAOYSA-N 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229940127090 anticoagulant agent Drugs 0.000 description 3
- 229960004676 antithrombotic agent Drugs 0.000 description 3
- 150000001500 aryl chlorides Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- LNGNZSMIUVQZOX-UHFFFAOYSA-L disodium;dioxido(sulfanylidene)-$l^{4}-sulfane Chemical compound [Na+].[Na+].[O-]S([O-])=S LNGNZSMIUVQZOX-UHFFFAOYSA-L 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 125000005553 heteroaryloxy group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 3
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009862 primary prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000009863 secondary prevention Effects 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 3
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 3
- 208000004043 venous thromboembolism Diseases 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- KJSQBNQYVIRDPB-UHFFFAOYSA-N (2-bromo-4-chloro-7,8-dihydro-[1,4]dioxino[2,3-g][1,3]benzothiazol-7-yl)methanol Chemical compound OCC1COc2c(O1)cc(Cl)c1nc(Br)sc21 KJSQBNQYVIRDPB-UHFFFAOYSA-N 0.000 description 2
- SUUVYOQCEZQGDE-UHFFFAOYSA-N (5-methylpyridin-3-yl) carbamate Chemical compound CC1=CN=CC(OC(N)=O)=C1 SUUVYOQCEZQGDE-UHFFFAOYSA-N 0.000 description 2
- DFYIFGSROHDOHI-UHFFFAOYSA-N (6-methoxypyridin-3-yl) carbamate Chemical compound C(N)(OC=1C=NC(=CC=1)OC)=O DFYIFGSROHDOHI-UHFFFAOYSA-N 0.000 description 2
- QIOGWFMWWQZYDC-UHFFFAOYSA-N (6-thiophen-2-ylpyridin-3-yl) carbamate Chemical compound C(N)(OC=1C=NC(=CC=1)C=1SC=CC=1)=O QIOGWFMWWQZYDC-UHFFFAOYSA-N 0.000 description 2
- RIFLNDAPBUQLJW-UHFFFAOYSA-N 1,3-thiazol-5-ylcarbamic acid Chemical compound OC(=O)NC1=CN=CS1 RIFLNDAPBUQLJW-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 2
- GWTXHANAAMJDHR-UHFFFAOYSA-N 2-(2-methoxy-7-methylquinoxalin-5-yl)-7,7-dimethyl-8H-furo[2,3-g][1,3]benzothiazole Chemical compound COC1=NC2=CC(=CC(=C2N=C1)C=1SC2=C(N=1)C=CC1=C2CC(O1)(C)C)C GWTXHANAAMJDHR-UHFFFAOYSA-N 0.000 description 2
- LKISOLAMBRVZOM-UHFFFAOYSA-N 2-(methoxymethyl)-7-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline Chemical compound COCC1=NC2=CC(=CC(=C2N=C1)B1OC(C(O1)(C)C)(C)C)C LKISOLAMBRVZOM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- VFPKZASVVCBVMG-UHFFFAOYSA-N 2-bromo-4-methyl-6-nitroaniline Chemical compound CC1=CC(Br)=C(N)C([N+]([O-])=O)=C1 VFPKZASVVCBVMG-UHFFFAOYSA-N 0.000 description 2
- ILEIUTCVWLYZOM-UHFFFAOYSA-N 2-hydroxy-5-methylbenzaldehyde Chemical compound CC1=CC=C(O)C(C=O)=C1 ILEIUTCVWLYZOM-UHFFFAOYSA-N 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ZJVJXEHHKVBTGM-UHFFFAOYSA-N 5-bromo-2-(methoxymethyl)-7-methylquinoxaline Chemical compound BrC1=C2N=CC(=NC2=CC(=C1)C)COC ZJVJXEHHKVBTGM-UHFFFAOYSA-N 0.000 description 2
- ZHVOCNVTYJHCGA-UHFFFAOYSA-N 5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,7-dimethyl-8H-furo[2,3-g][1,3]benzothiazole Chemical compound FC1=CC=2N=C(SC=2C=2CC(OC=21)(C)C)C1=C2N=CC(=NC2=CC(=C1)C)OC ZHVOCNVTYJHCGA-UHFFFAOYSA-N 0.000 description 2
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 2
- QSXIBAPXTTVDTO-UHFFFAOYSA-N 7,8-dihydrofuro[2,3-g][1,3]benzothiazole Chemical group S1C=NC2=C1C=1CCOC=1C=C2 QSXIBAPXTTVDTO-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- ZOLUFSYYKUNBSE-UHFFFAOYSA-N C(N)(OC=1C=NC(=C(C=1)C)C)=O Chemical compound C(N)(OC=1C=NC(=C(C=1)C)C)=O ZOLUFSYYKUNBSE-UHFFFAOYSA-N 0.000 description 2
- SZQKLCQSCLPUDZ-UHFFFAOYSA-N CC1=CC(=CN=C1F)OC(=O)N Chemical compound CC1=CC(=CN=C1F)OC(=O)N SZQKLCQSCLPUDZ-UHFFFAOYSA-N 0.000 description 2
- BIQPLYJJXACRIL-UHFFFAOYSA-N CN1C=NC2=C1N=CC(=C2)OC(=O)N Chemical compound CN1C=NC2=C1N=CC(=C2)OC(=O)N BIQPLYJJXACRIL-UHFFFAOYSA-N 0.000 description 2
- 101100456282 Caenorhabditis elegans mcm-4 gene Proteins 0.000 description 2
- 206010007688 Carotid artery thrombosis Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- IWKRSDRQNDVIHJ-QGZVFWFLSA-N N-[[(7R)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methyl]-2-phenylacetamide Chemical compound FC1=CC=2N=C(SC=2C=2C[C@@H](OC=21)CNC(CC1=CC=CC=C1)=O)C1=C2N=CC(=NC2=CC(=C1)C)OC IWKRSDRQNDVIHJ-QGZVFWFLSA-N 0.000 description 2
- XUKKJIZDCNQDSE-LBPRGKRZSA-N N-[[(7S)-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methyl]methanesulfonamide Chemical compound CS(=O)(=O)NC[C@H]1OC2=C(C1)C1=C(N=C(S1)C1=C3N=CC(=NC3=CC(=C1)C)OC)C=C2 XUKKJIZDCNQDSE-LBPRGKRZSA-N 0.000 description 2
- HTHMMHFOYQYNMM-AWEZNQCLSA-N N-[[(7S)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methyl]morpholine-4-carboxamide Chemical compound N1(CCOCC1)C(=O)NC[C@H]1OC2=C(C1)C1=C(N=C(S1)C1=C3N=CC(=NC3=CC(=C1)C)OC)C=C2F HTHMMHFOYQYNMM-AWEZNQCLSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000008212 P-Selectin Human genes 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229940098892 Protease-activated receptor-1 antagonist Drugs 0.000 description 2
- 206010038460 Renal haemorrhage Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 102000049398 Vasodilator-stimulated phosphoproteins Human genes 0.000 description 2
- JANLPHZWGSKYQR-OAQYLSRUSA-N [(7R)-2-(2-methoxy-7-methylquinoxalin-5-yl)-7-methyl-8H-furo[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound COc1cnc2c(cc(C)cc2n1)-c1nc2ccc3O[C@@](C)(CO)Cc3c2s1 JANLPHZWGSKYQR-OAQYLSRUSA-N 0.000 description 2
- HDDXOSWIDIGFDE-GFCCVEGCSA-N [(7R)-2-(6-chloro-3-methoxyquinolin-8-yl)-5-fluoro-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound ClC=1C=C2C=C(C=NC2=C(C=1)C=1SC2=C(N=1)C=C(C1=C2C[C@@H](O1)CO)F)OC HDDXOSWIDIGFDE-GFCCVEGCSA-N 0.000 description 2
- VOYBTRVPLJXDPV-LJQANCHMSA-N [(7R)-4-chloro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydro-[1,4]dioxino[2,3-g][1,3]benzothiazol-7-yl] N-methyl-N-pyridazin-4-ylcarbamate Chemical compound CN(C(O[C@H]1OC2=C(C3=C(N=C(S3)C3=C4N=CC(=NC4=CC(=C3)C)OC)C(=C2)Cl)OC1)=O)C1=CN=NC=C1 VOYBTRVPLJXDPV-LJQANCHMSA-N 0.000 description 2
- IBJHTQKAZCZOSV-HNNXBMFYSA-N [(7R)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-8,8-dimethyl-7H-furo[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound FC1=CC=2N=C(SC=2C=2C([C@@H](OC=21)CO)(C)C)C1=C2N=CC(=NC2=CC(=C1)C)OC IBJHTQKAZCZOSV-HNNXBMFYSA-N 0.000 description 2
- YYIYJSQEJAIUQL-NSHDSACASA-N [(7S)-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound COc1cnc2c(cc(C)cc2n1)-c1nc2ccc3O[C@H](CO)Cc3c2s1 YYIYJSQEJAIUQL-NSHDSACASA-N 0.000 description 2
- CEJYKZJDMKBMQW-JTQLQIEISA-N [(7S)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound FC1=CC=2N=C(SC=2C=2C[C@H](OC=21)CO)C1=C2N=CC(=NC2=CC(=C1)C)OC CEJYKZJDMKBMQW-JTQLQIEISA-N 0.000 description 2
- JANLPHZWGSKYQR-UHFFFAOYSA-N [2-(2-methoxy-7-methylquinoxalin-5-yl)-7-methyl-8H-furo[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound COC1=NC2=CC(=CC(=C2N=C1)C=1SC2=C(N=1)C=CC1=C2CC(O1)(C)CO)C JANLPHZWGSKYQR-UHFFFAOYSA-N 0.000 description 2
- GBGYEPMGCVEGTH-UHFFFAOYSA-N [5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7-methyl-8H-furo[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound FC1=CC=2N=C(SC=2C=2CC(OC=21)(C)CO)C1=C2N=CC(=NC2=CC(=C1)C)OC GBGYEPMGCVEGTH-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940125890 compound Ia Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 239000007819 coupling partner Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BJZCVSWNTPRACJ-UHFFFAOYSA-N methyl n-pyridin-3-ylcarbamate Chemical compound COC(=O)NC1=CC=CN=C1 BJZCVSWNTPRACJ-UHFFFAOYSA-N 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000003615 platelet activation assay Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- FKSXRCPGQMOMBI-UHFFFAOYSA-N pyridin-4-ylcarbamic acid Chemical compound OC(=O)NC1=CC=NC=C1 FKSXRCPGQMOMBI-UHFFFAOYSA-N 0.000 description 2
- 150000003252 quinoxalines Chemical class 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229950008418 talipexole Drugs 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 description 2
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 description 2
- 229960005044 vorapaxar Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- AHKCYLDVGMDNIE-UHFFFAOYSA-N (2-bromo-4-methyl-7,8-dihydro-[1,4]dioxino[2,3-g][1,3]benzothiazol-7-yl)methanol Chemical compound Cc1cc2OC(CO)COc2c2sc(Br)nc12 AHKCYLDVGMDNIE-UHFFFAOYSA-N 0.000 description 1
- VUAVBIKPKROADH-UHFFFAOYSA-N (2-chloro-6,7-dimethoxy-1,3-benzothiazol-4-yl)methanol Chemical compound ClC=1SC2=C(N=1)C(=CC(=C2OC)OC)CO VUAVBIKPKROADH-UHFFFAOYSA-N 0.000 description 1
- ZQZOQPRAODRJQI-UHFFFAOYSA-N (2-ethoxycarbonyl-7-methylquinoxalin-5-yl)boronic acid Chemical compound C(C)OC(=O)C1=NC2=CC(=CC(=C2N=C1)B(O)O)C ZQZOQPRAODRJQI-UHFFFAOYSA-N 0.000 description 1
- XTGAPFYXJBHXEU-UHFFFAOYSA-N (2-methoxy-7-methylquinoxalin-5-yl)boronic acid Chemical compound COC1=NC2=CC(=CC(=C2N=C1)B(O)O)C XTGAPFYXJBHXEU-UHFFFAOYSA-N 0.000 description 1
- LBJKOXYXLQFXGM-UHFFFAOYSA-N (2-methoxypyridin-4-yl) carbamate Chemical compound COC1=CC(OC(N)=O)=CC=N1 LBJKOXYXLQFXGM-UHFFFAOYSA-N 0.000 description 1
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 1
- SBEFKZIMGNWXFF-UHFFFAOYSA-N (5-bromo-7-methylquinoxalin-2-yl)methanol Chemical compound BrC1=C2N=CC(=NC2=CC(=C1)C)CO SBEFKZIMGNWXFF-UHFFFAOYSA-N 0.000 description 1
- KOWNPZCRJSQDQM-UHFFFAOYSA-N (5-bromo-7-methylquinoxalin-2-yl)methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=NC2=CC(=CC(=C2N=C1)Br)C KOWNPZCRJSQDQM-UHFFFAOYSA-N 0.000 description 1
- PZCDJQHFOZBTQK-UHFFFAOYSA-N (6-aminopyridin-3-yl) carbamate Chemical compound C(N)(OC=1C=NC(=CC=1)N)=O PZCDJQHFOZBTQK-UHFFFAOYSA-N 0.000 description 1
- HRDIIEFKMSSDPJ-UHFFFAOYSA-N (6-bromopyridin-3-yl) carbamate Chemical compound C(N)(OC=1C=NC(=CC=1)Br)=O HRDIIEFKMSSDPJ-UHFFFAOYSA-N 0.000 description 1
- UAPKPWQRKCZUEU-UHFFFAOYSA-N (6-chloro-2,3-dihydro-1,4-benzodioxin-3-yl)methanol Chemical compound C1=C(Cl)C=C2OC(CO)COC2=C1 UAPKPWQRKCZUEU-UHFFFAOYSA-N 0.000 description 1
- OQNLEEFFMIVNRF-UHFFFAOYSA-N (6-methyl-2,3-dihydro-1,4-benzodioxin-3-yl)methanol Chemical compound O1CC(CO)OC2=CC(C)=CC=C21 OQNLEEFFMIVNRF-UHFFFAOYSA-N 0.000 description 1
- BNEDKHNAJQNSKF-UHFFFAOYSA-N (8-chloro-3-methoxyquinoxalin-6-yl)methanol Chemical compound COc1cnc2c(Cl)cc(CO)cc2n1 BNEDKHNAJQNSKF-UHFFFAOYSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- VLROMOUGVDIWFF-UHFFFAOYSA-N 1,3-benzoxazol-5-ylcarbamic acid Chemical compound OC(=O)NC1=CC=C2OC=NC2=C1 VLROMOUGVDIWFF-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- GFKJXXMXCMOGCA-UHFFFAOYSA-N 1-(2-bromo-6,7-dihydroxy-1,3-benzothiazol-4-yl)-2,2-dimethylpropan-1-one Chemical compound CC(C)(C)C(=O)C1=C2N=C(Br)SC2=C(O)C(O)=C1 GFKJXXMXCMOGCA-UHFFFAOYSA-N 0.000 description 1
- MLCQAFNRNOCGIH-UHFFFAOYSA-N 1-(2-chloro-6,7-dimethoxy-1,3-benzothiazol-4-yl)-2,2-dimethylpropan-1-ol Chemical compound COC1=CC(C(O)C(C)(C)C)=C2N=C(Cl)SC2=C1OC MLCQAFNRNOCGIH-UHFFFAOYSA-N 0.000 description 1
- IMGGPTZQKRZKSJ-UHFFFAOYSA-N 1-[2-(2-methoxy-7-methylquinoxalin-5-yl)-8,9-dihydro-7H-[1,4]dioxepino[2,3-g][1,3]benzothiazol-4-yl]-2,2-dimethylpropan-1-ol Chemical compound COC1=NC2=CC(=CC(=C2N=C1)C=1SC2=C(N=1)C(=CC1=C2OCCCO1)C(C(C)(C)C)O)C IMGGPTZQKRZKSJ-UHFFFAOYSA-N 0.000 description 1
- KUQQZWZEUIQCGW-UHFFFAOYSA-N 1-[7-(2-methoxy-7-methylquinoxalin-5-yl)-[1,3]dioxolo[4,5-g][1,3]benzothiazol-5-yl]-2,2-dimethylpropan-1-ol Chemical compound C1OC2=C3C(=C(C(C(C)(C)C)O)C=C2O1)N=C(S3)C1=CC(C)=CC2=NC(=CN=C12)OC KUQQZWZEUIQCGW-UHFFFAOYSA-N 0.000 description 1
- JLDBOILDSLEJHT-UHFFFAOYSA-N 1-bromo-3-methoxypropan-2-one Chemical compound COCC(=O)CBr JLDBOILDSLEJHT-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- PRSOZYPURFFAPH-UHFFFAOYSA-N 1-diazonio-3-methoxyprop-1-en-2-olate Chemical compound COCC([O-])=C[N+]#N PRSOZYPURFFAPH-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical group COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GWQOQQVKVOOHTI-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ylmethanol Chemical compound C1=CC=C2OC(CO)COC2=C1 GWQOQQVKVOOHTI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QIRNGVVZBINFMX-UHFFFAOYSA-N 2-allylphenol Chemical compound OC1=CC=CC=C1CC=C QIRNGVVZBINFMX-UHFFFAOYSA-N 0.000 description 1
- RQBXDAJHWRFLQL-UHFFFAOYSA-N 2-bromo-3,4-dimethyl-6-nitroaniline Chemical compound CC1=CC([N+]([O-])=O)=C(N)C(Br)=C1C RQBXDAJHWRFLQL-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- MCALXGRQNXDTPI-UHFFFAOYSA-N 2-iodo-4-methyl-6-nitroaniline Chemical compound CC1=CC(I)=C(N)C([N+]([O-])=O)=C1 MCALXGRQNXDTPI-UHFFFAOYSA-N 0.000 description 1
- GAIVNYMXRBKPGI-UHFFFAOYSA-N 2-methoxy-6,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline Chemical compound COC1=NC2=CC(C)=C(C)C(B3OC(C)(C)C(C)(C)O3)=C2N=C1 GAIVNYMXRBKPGI-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- DLURHXYXQYMPLT-UHFFFAOYSA-N 2-nitro-p-toluidine Chemical compound CC1=CC=C(N)C([N+]([O-])=O)=C1 DLURHXYXQYMPLT-UHFFFAOYSA-N 0.000 description 1
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WHVCTNJQZXBGDH-UHFFFAOYSA-N 3-bromo-5-methylbenzene-1,2-diamine Chemical compound CC1=CC(N)=C(N)C(Br)=C1 WHVCTNJQZXBGDH-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- MDUMNVHZXIAVKS-UHFFFAOYSA-N 3-methoxy-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline-6-carbonitrile Chemical compound COC1=NC2=CC(=CC(B3OC(C)(C)C(C)(C)O3)=C2N=C1)C#N MDUMNVHZXIAVKS-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- PINGKGKKUSYUAW-UHFFFAOYSA-N 4,5-dimethyl-2-nitroaniline Chemical compound CC1=CC(N)=C([N+]([O-])=O)C=C1C PINGKGKKUSYUAW-UHFFFAOYSA-N 0.000 description 1
- JAHADAZIDZMHOP-UHFFFAOYSA-N 4-amino-3-nitrobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1[N+]([O-])=O JAHADAZIDZMHOP-UHFFFAOYSA-N 0.000 description 1
- QGMGHALXLXKCBD-UHFFFAOYSA-N 4-amino-n-(2-aminophenyl)benzamide Chemical compound C1=CC(N)=CC=C1C(=O)NC1=CC=CC=C1N QGMGHALXLXKCBD-UHFFFAOYSA-N 0.000 description 1
- DTMANVRIDHGRKN-UHFFFAOYSA-N 4-bromo-3-fluoro-2-nitroaniline Chemical compound NC1=CC=C(Br)C(F)=C1[N+]([O-])=O DTMANVRIDHGRKN-UHFFFAOYSA-N 0.000 description 1
- BXJUAIVCBVNZNT-UHFFFAOYSA-N 4-bromo-6-chloro-3-fluoro-2-nitroaniline Chemical compound BrC1=C(C(=C(N)C(=C1)Cl)[N+](=O)[O-])F BXJUAIVCBVNZNT-UHFFFAOYSA-N 0.000 description 1
- XTTWGRVAALBLCK-UHFFFAOYSA-N 4-bromo-7,8-dihydro-[1,4]dioxino[2,3-g][1,3]benzothiazol-2-amine Chemical compound O1CCOC2=C(SC(N)=N3)C3=C(Br)C=C21 XTTWGRVAALBLCK-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- WEYNXPCJKFBQLC-UHFFFAOYSA-N 5-bromo-2,7-dimethylquinoxaline Chemical compound BrC1=C2N=CC(=NC2=CC(=C1)C)C WEYNXPCJKFBQLC-UHFFFAOYSA-N 0.000 description 1
- WNGUAQWTYCQLHT-UHFFFAOYSA-N 5-bromo-2-(difluoromethoxy)-7-methylquinoxaline Chemical compound N1=CC(OC(F)F)=NC2=CC(C)=CC(Br)=C21 WNGUAQWTYCQLHT-UHFFFAOYSA-N 0.000 description 1
- KXMJUSWQPYFXMT-UHFFFAOYSA-N 5-bromo-2-methoxy-6,7-dimethylquinoxaline Chemical compound BrC1=C2N=CC(=NC2=CC(=C1C)C)OC KXMJUSWQPYFXMT-UHFFFAOYSA-N 0.000 description 1
- NLMPEMWIPLRJHG-UHFFFAOYSA-N 5-bromo-2-methoxy-7-methylquinoxaline Chemical compound BrC1=C2N=CC(=NC2=CC(=C1)C)OC NLMPEMWIPLRJHG-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- NCLJNBKBUYYEOP-UHFFFAOYSA-N 5-bromo-6,7-dimethyl-1H-quinoxalin-2-one Chemical compound Cc1cc2[nH]c(=O)cnc2c(Br)c1C NCLJNBKBUYYEOP-UHFFFAOYSA-N 0.000 description 1
- SHDLTGCNAKPKRT-UHFFFAOYSA-N 5-bromo-6,7-dimethyl-3,4-dihydro-1H-quinoxalin-2-one Chemical compound BrC1=C2NCC(NC2=CC(=C1C)C)=O SHDLTGCNAKPKRT-UHFFFAOYSA-N 0.000 description 1
- UCSBJEVQHJWSQU-UHFFFAOYSA-N 5-bromo-7-chloro-1H-quinoxalin-2-one Chemical compound BrC1=C2N=CC(=NC2=CC(=C1)Cl)O UCSBJEVQHJWSQU-UHFFFAOYSA-N 0.000 description 1
- QEWVTMSJAKAKIG-UHFFFAOYSA-N 5-bromo-7-chloro-2-(methoxymethyl)quinoxaline Chemical compound COCC1=NC2=CC(Cl)=CC(Br)=C2N=C1 QEWVTMSJAKAKIG-UHFFFAOYSA-N 0.000 description 1
- KYTRINCTPLXMSN-UHFFFAOYSA-N 5-bromo-7-chloro-2-methoxyquinoxaline Chemical compound COc1cnc2c(Br)cc(Cl)cc2n1 KYTRINCTPLXMSN-UHFFFAOYSA-N 0.000 description 1
- VFSOYPKMRSXMAD-UHFFFAOYSA-N 5-bromo-7-chloro-3,4-dihydro-1H-quinoxalin-2-one Chemical compound BrC1=C2NCC(NC2=CC(=C1)Cl)=O VFSOYPKMRSXMAD-UHFFFAOYSA-N 0.000 description 1
- IEDNWPALLMAQCQ-UHFFFAOYSA-N 5-bromo-7-methyl-1h-quinoxalin-2-one Chemical compound N1=CC(O)=NC2=CC(C)=CC(Br)=C21 IEDNWPALLMAQCQ-UHFFFAOYSA-N 0.000 description 1
- PNKYPSYRAZIBJD-UHFFFAOYSA-N 5-bromo-7-methyl-3,4-dihydro-1h-quinoxalin-2-one Chemical compound N1CC(=O)NC2=CC(C)=CC(Br)=C21 PNKYPSYRAZIBJD-UHFFFAOYSA-N 0.000 description 1
- MYCJGUWVMZIHCT-UHFFFAOYSA-N 5-chloro-2-(oxiran-2-ylmethoxy)benzaldehyde Chemical compound O=CC1=CC(Cl)=CC=C1OCC1OC1 MYCJGUWVMZIHCT-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- FUGKCSRLAQKUHG-UHFFFAOYSA-N 5-chloro-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Cl)C=C1C=O FUGKCSRLAQKUHG-UHFFFAOYSA-N 0.000 description 1
- SVUXYSNAESLTFJ-UHFFFAOYSA-N 5-chloro-7-ethenyl-2-methoxyquinoxaline Chemical compound ClC1=C2N=CC(=NC2=CC(=C1)C=C)OC SVUXYSNAESLTFJ-UHFFFAOYSA-N 0.000 description 1
- HDYGDQRXTZYLSJ-UHFFFAOYSA-N 5-chloro-7-ethenyl-8-fluoro-2-methoxyquinoxaline Chemical compound ClC1=C2N=CC(=NC2=C(C(=C1)C=C)F)OC HDYGDQRXTZYLSJ-UHFFFAOYSA-N 0.000 description 1
- NTGJJQOKFLTKNG-UHFFFAOYSA-N 5-iodo-7-methyl-1H-quinoxalin-2-one Chemical compound IC1=C2N=CC(NC2=CC(=C1)C)=O NTGJJQOKFLTKNG-UHFFFAOYSA-N 0.000 description 1
- PEJIOACDNGLRDH-UHFFFAOYSA-N 5-iodo-7-methyl-3,4-dihydro-1H-quinoxalin-2-one Chemical compound IC1=C2NCC(NC2=CC(=C1)C)=O PEJIOACDNGLRDH-UHFFFAOYSA-N 0.000 description 1
- WEEHXSRKESWXKK-UHFFFAOYSA-N 5-methyl-2-(oxiran-2-ylmethoxy)benzaldehyde Chemical compound O=CC1=CC(C)=CC=C1OCC1OC1 WEEHXSRKESWXKK-UHFFFAOYSA-N 0.000 description 1
- WEEHXSRKESWXKK-SNVBAGLBSA-N 5-methyl-2-[[(2r)-oxiran-2-yl]methoxy]benzaldehyde Chemical compound O=CC1=CC(C)=CC=C1OC[C@@H]1OC1 WEEHXSRKESWXKK-SNVBAGLBSA-N 0.000 description 1
- RSBPTTBZKJYYLM-UHFFFAOYSA-N 6-bromo-2,3-dihydro-1,4-benzodioxin-7-amine Chemical compound O1CCOC2=C1C=C(N)C(Br)=C2 RSBPTTBZKJYYLM-UHFFFAOYSA-N 0.000 description 1
- PBFAMONJVJBDQV-UHFFFAOYSA-N 6-bromo-7-nitro-2,3-dihydro-1,4-benzodioxine Chemical compound O1CCOC2=C1C=C([N+](=O)[O-])C(Br)=C2 PBFAMONJVJBDQV-UHFFFAOYSA-N 0.000 description 1
- RMQVTHLCYGSTMS-UHFFFAOYSA-N 7-bromo-5-chloro-1H-quinoxalin-2-one Chemical compound BrC1=CC(=C2N=CC(NC2=C1)=O)Cl RMQVTHLCYGSTMS-UHFFFAOYSA-N 0.000 description 1
- LAILUTZSWLJHMF-UHFFFAOYSA-N 7-bromo-5-chloro-2-methoxyquinoxaline Chemical compound COc1cnc2c(Cl)cc(Br)cc2n1 LAILUTZSWLJHMF-UHFFFAOYSA-N 0.000 description 1
- FUEARBBMINXBCO-UHFFFAOYSA-N 7-bromo-5-chloro-3,4-dihydro-1H-quinoxalin-2-one Chemical compound BrC1=CC(=C2NCC(NC2=C1)=O)Cl FUEARBBMINXBCO-UHFFFAOYSA-N 0.000 description 1
- DXGJFFCMKBHGAL-UHFFFAOYSA-N 7-bromo-5-chloro-8-fluoro-1H-quinoxalin-2-one Chemical compound BrC1=CC(=C2N=CC(NC2=C1F)=O)Cl DXGJFFCMKBHGAL-UHFFFAOYSA-N 0.000 description 1
- HXGAIQQGNIPXBI-UHFFFAOYSA-N 7-bromo-5-chloro-8-fluoro-3,4-dihydro-1H-quinoxalin-2-one Chemical compound Fc1c(Br)cc(Cl)c2NCC(=O)Nc12 HXGAIQQGNIPXBI-UHFFFAOYSA-N 0.000 description 1
- GVBOMYOKDSUGMR-UHFFFAOYSA-N 7-chloro-2-(methoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline Chemical compound COCC1=NC2=CC(Cl)=CC(B3OC(C)(C)C(C)(C)O3)=C2N=C1 GVBOMYOKDSUGMR-UHFFFAOYSA-N 0.000 description 1
- MBIKINCTKQEJQN-UHFFFAOYSA-N 7-chloro-2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline Chemical compound COC1=NC2=CC(Cl)=CC(B3OC(C)(C)C(C)(C)O3)=C2N=C1 MBIKINCTKQEJQN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- AXMDFASQFFRPLB-UHFFFAOYSA-N 8-bromo-3-methoxyquinoxaline-6-carbaldehyde Chemical compound BrC=1C=C(C=C2N=C(C=NC=12)OC)C=O AXMDFASQFFRPLB-UHFFFAOYSA-N 0.000 description 1
- GBQZTMHWISWVEG-UHFFFAOYSA-N 8-bromo-3-oxo-2,4-dihydro-1H-quinoxaline-6-carbonitrile Chemical compound BrC1=CC(=CC2=C1NCC(=O)N2)C#N GBQZTMHWISWVEG-UHFFFAOYSA-N 0.000 description 1
- JJRQNGIFLCLABZ-UHFFFAOYSA-N 8-bromo-3-oxo-4H-quinoxaline-6-carbonitrile Chemical compound BrC=1C=C(C=C2NC(C=NC=12)=O)C#N JJRQNGIFLCLABZ-UHFFFAOYSA-N 0.000 description 1
- OURZDNVZPBIGLL-UHFFFAOYSA-N 8-chloro-3-methoxyquinoxaline-6-carbaldehyde Chemical compound ClC=1C=C(C=C2N=C(C=NC=12)OC)C=O OURZDNVZPBIGLL-UHFFFAOYSA-N 0.000 description 1
- ZDKZQKHAHSIVJJ-UHFFFAOYSA-N 8-chloro-5-fluoro-3-methoxyquinoxaline-6-carbaldehyde Chemical compound ClC=1C=C(C(=C2N=C(C=NC=12)OC)F)C=O ZDKZQKHAHSIVJJ-UHFFFAOYSA-N 0.000 description 1
- ONMOULMPIIOVTQ-UHFFFAOYSA-N 98-47-5 Chemical compound OS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 ONMOULMPIIOVTQ-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- QWKAUGRRIXBIPO-UHFFFAOYSA-N Atopaxar Chemical compound N=C1C=2C(F)=C(OCC)C(OCC)=CC=2CN1CC(=O)C(C=C(C=1OC)C(C)(C)C)=CC=1N1CCOCC1 QWKAUGRRIXBIPO-UHFFFAOYSA-N 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- COELPOHKYHPEIG-UHFFFAOYSA-N C1=C(C=NC(=N1)CCO)OC(=O)N Chemical compound C1=C(C=NC(=N1)CCO)OC(=O)N COELPOHKYHPEIG-UHFFFAOYSA-N 0.000 description 1
- UQFTYCNVJAIGEY-UHFFFAOYSA-N C1=C(C=NC=C1OC(=O)N)C#N Chemical compound C1=C(C=NC=C1OC(=O)N)C#N UQFTYCNVJAIGEY-UHFFFAOYSA-N 0.000 description 1
- RBDFFVABHQYUOR-UHFFFAOYSA-N C1=CC(=NC=C1OC(=O)N)OCC(CO)(F)F Chemical compound C1=CC(=NC=C1OC(=O)N)OCC(CO)(F)F RBDFFVABHQYUOR-UHFFFAOYSA-N 0.000 description 1
- IROCPMLJWPOPMS-UHFFFAOYSA-N C1=CC(=NC=C1OC(=O)N)OCCO Chemical compound C1=CC(=NC=C1OC(=O)N)OCCO IROCPMLJWPOPMS-UHFFFAOYSA-N 0.000 description 1
- RUNYCSJZHMLEKX-UHFFFAOYSA-N C1CCN(C1)C2=NC=C(C=C2)OC(=O)N Chemical compound C1CCN(C1)C2=NC=C(C=C2)OC(=O)N RUNYCSJZHMLEKX-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 238000005821 Claisen rearrangement reaction Methods 0.000 description 1
- 102000009268 Collagen Receptors Human genes 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010070954 Congenital hypercoagulation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- YLURNFCYLWIOCS-UHFFFAOYSA-N FC(OC1=NC2=CC(=CC(=C2N=C1)B1OC(C(O1)(C)C)(C)C)C)F Chemical compound FC(OC1=NC2=CC(=CC(=C2N=C1)B1OC(C(O1)(C)C)(C)C)C)F YLURNFCYLWIOCS-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001272178 Glires Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101100407050 Homo sapiens F2RL3 gene Proteins 0.000 description 1
- 101100518982 Homo sapiens PAWR gene Proteins 0.000 description 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010056997 Impaired fasting glucose Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000011682 Mitral valve disease Diseases 0.000 description 1
- RPLZWPRURWHSQI-GFCCVEGCSA-N N-[[(7R)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methyl]acetamide Chemical compound FC1=CC=2N=C(SC=2C=2C[C@@H](OC=21)CNC(C)=O)C1=C2N=CC(=NC2=CC(=C1)C)OC RPLZWPRURWHSQI-GFCCVEGCSA-N 0.000 description 1
- RPLZWPRURWHSQI-LBPRGKRZSA-N N-[[(7S)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7,8-dihydrofuro[2,3-g][1,3]benzothiazol-7-yl]methyl]acetamide Chemical compound FC1=CC=2N=C(SC=2C=2C[C@H](OC=21)CNC(C)=O)C1=C2N=CC(=NC2=CC(=C1)C)OC RPLZWPRURWHSQI-LBPRGKRZSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- SOZOESGACJISOJ-UHFFFAOYSA-N NC(OC(C=N1)=CC=C1F)=O Chemical compound NC(OC(C=N1)=CC=C1F)=O SOZOESGACJISOJ-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 108050008996 P2Y purinoceptor 1 Proteins 0.000 description 1
- 101710162991 PRKC apoptosis WT1 regulator protein Proteins 0.000 description 1
- 102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010045766 Platelet Glycoprotein GPIb-IX Complex Proteins 0.000 description 1
- 102000023159 Platelet Glycoprotein GPIb-IX Complex Human genes 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004885 Protease-activated receptor 4 Human genes 0.000 description 1
- 108090001010 Protease-activated receptor 4 Proteins 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 101100485158 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) wzzE gene Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- 101100275767 Synechocystis sp. (strain PCC 6803 / Kazusa) crhR gene Proteins 0.000 description 1
- 102000003790 Thrombin receptors Human genes 0.000 description 1
- 108090000166 Thrombin receptors Proteins 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 108010059382 Zea mays trypsin inhibitor Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- OQNLEEFFMIVNRF-QMMMGPOBSA-N [(3s)-6-methyl-2,3-dihydro-1,4-benzodioxin-3-yl]methanol Chemical compound O1C[C@H](CO)OC2=CC(C)=CC=C21 OQNLEEFFMIVNRF-QMMMGPOBSA-N 0.000 description 1
- GBGYEPMGCVEGTH-OAQYLSRUSA-N [(7R)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7-methyl-8H-furo[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound FC1=CC=2N=C(SC=2C=2C[C@](OC=21)(C)CO)C1=C2N=CC(=NC2=CC(=C1)C)OC GBGYEPMGCVEGTH-OAQYLSRUSA-N 0.000 description 1
- GWBRYYMKCDDDCA-NRFANRHFSA-N [(7S)-2-(6-chloro-3-methoxyquinolin-8-yl)-5-fluoro-7-methyl-8H-furo[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound ClC=1C=C2C=C(C=NC2=C(C=1)C=1SC2=C(N=1)C=C(C1=C2C[C@@](O1)(C)CO)F)OC GWBRYYMKCDDDCA-NRFANRHFSA-N 0.000 description 1
- GBGYEPMGCVEGTH-NRFANRHFSA-N [(7S)-5-fluoro-2-(2-methoxy-7-methylquinoxalin-5-yl)-7-methyl-8H-furo[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound FC1=CC=2N=C(SC=2C=2C[C@@](OC=21)(C)CO)C1=C2N=CC(=NC2=CC(=C1)C)OC GBGYEPMGCVEGTH-NRFANRHFSA-N 0.000 description 1
- MQUYHNNJRXUVGV-UHFFFAOYSA-N [1,4]dioxino[2,3-g][1,3]benzothiazole Chemical compound O1C=COC2=C1C=CC1=C2SC=N1 MQUYHNNJRXUVGV-UHFFFAOYSA-N 0.000 description 1
- JAXYWRKRWWTUBX-UHFFFAOYSA-N [2-(1-benzylindazol-3-yl)furan-3-yl]methanol Chemical class C1=COC(C=2C3=CC=CC=C3N(CC=3C=CC=CC=3)N=2)=C1CO JAXYWRKRWWTUBX-UHFFFAOYSA-N 0.000 description 1
- TYFFFBCDPWILJJ-UHFFFAOYSA-N [2-(2-methoxy-7-methylquinoxalin-5-yl)-4-methyl-7,8-dihydro-[1,4]dioxino[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound COc1cnc2c(cc(C)cc2n1)-c1nc2c(C)cc3OC(CO)COc3c2s1 TYFFFBCDPWILJJ-UHFFFAOYSA-N 0.000 description 1
- GHLQVADZGZIAJP-UHFFFAOYSA-N [2-[2-(difluoromethoxy)-7-methylquinoxalin-5-yl]-4-methyl-7,8-dihydro-[1,4]dioxino[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound Cc1cc(-c2nc3c(C)cc4OC(CO)COc4c3s2)c2ncc(OC(F)F)nc2c1 GHLQVADZGZIAJP-UHFFFAOYSA-N 0.000 description 1
- SFBSOAOVXQTSCY-UHFFFAOYSA-N [4-(methylcarbamoyl)phenyl] carbamate Chemical compound CNC(=O)C1=CC=C(OC(N)=O)C=C1 SFBSOAOVXQTSCY-UHFFFAOYSA-N 0.000 description 1
- DMTRZALLLUMGAG-UHFFFAOYSA-N [4-chloro-2-[2-(difluoromethoxy)-7-methylquinoxalin-5-yl]-7,8-dihydro-[1,4]dioxino[2,3-g][1,3]benzothiazol-7-yl]methanol Chemical compound Cc1cc(-c2nc3c(Cl)cc4OC(CO)COc4c3s2)c2ncc(OC(F)F)nc2c1 DMTRZALLLUMGAG-UHFFFAOYSA-N 0.000 description 1
- ONFZVEBRBGPFNC-UHFFFAOYSA-N [5-fluoro-3-methoxy-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-6-yl]methanol Chemical compound COC1=NC2=C(F)C(CO)=CC(B3OC(C)(C)C(C)(C)O3)=C2N=C1 ONFZVEBRBGPFNC-UHFFFAOYSA-N 0.000 description 1
- UILQEYAOJIXDDG-UHFFFAOYSA-N [6-(trifluoromethyl)pyridin-3-yl] carbamate Chemical compound NC(=O)OC1=CC=C(C(F)(F)F)N=C1 UILQEYAOJIXDDG-UHFFFAOYSA-N 0.000 description 1
- XMFHDDZZVUABFQ-UHFFFAOYSA-N [7-(hydroxymethyl)-2-methoxyquinoxalin-5-yl]boronic acid Chemical compound OCC1=CC(=C2N=CC(=NC2=C1)OC)B(O)O XMFHDDZZVUABFQ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229950007648 atopaxar Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQESKQAHRXOSMS-UHFFFAOYSA-N benzyltrimethylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)CC1=CC=CC=C1 OQESKQAHRXOSMS-UHFFFAOYSA-N 0.000 description 1
- 229950011103 betrixaban Drugs 0.000 description 1
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical group N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000004989 dicarbonyl group Chemical group 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- CXQRZKIIGJLWPJ-UHFFFAOYSA-N diphenylphosphane;1-naphthalen-1-ylnaphthalene Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1.C1=CC=C2C(C=3C4=CC=CC=C4C=CC=3)=CC=CC2=C1 CXQRZKIIGJLWPJ-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229960000622 edoxaban Drugs 0.000 description 1
- PSMMNJNZVZZNOI-SJILXJHISA-N edoxaban tosylate hydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 PSMMNJNZVZZNOI-SJILXJHISA-N 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- GEPBXEGBROUWNT-UHFFFAOYSA-N ethyl 5-bromo-7-methylquinoxaline-2-carboxylate Chemical compound BrC1=C2N=CC(=NC2=CC(=C1)C)C(=O)OCC GEPBXEGBROUWNT-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010002230 lepirudin Proteins 0.000 description 1
- FIBJDTSHOUXTKV-BRHMIFOHSA-N lepirudin Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC2=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O FIBJDTSHOUXTKV-BRHMIFOHSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 101150089110 metN gene Proteins 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- QQFHCCQSCQBKBG-UHFFFAOYSA-N methyl 2-amino-4,5-dimethoxybenzoate Chemical compound COC(=O)C1=CC(OC)=C(OC)C=C1N QQFHCCQSCQBKBG-UHFFFAOYSA-N 0.000 description 1
- NKXRSMGVKKLHCN-UHFFFAOYSA-N methyl 2-amino-6,7-dimethoxy-1,3-benzothiazole-4-carboxylate Chemical compound NC=1SC=2C(N=1)=C(C=C(C=2OC)OC)C(=O)OC NKXRSMGVKKLHCN-UHFFFAOYSA-N 0.000 description 1
- UAQWBBCXDRQYAA-UHFFFAOYSA-N methyl 2-chloro-6,7-dimethoxy-1,3-benzothiazole-4-carboxylate Chemical compound ClC=1SC=2C(N=1)=C(C=C(C=2OC)OC)C(=O)OC UAQWBBCXDRQYAA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- LLYKPZOWCPVRPD-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine;n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=CC=N1 LLYKPZOWCPVRPD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 238000007243 oxidative cyclization reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 229940030915 refludan Drugs 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000003572 second messenger assay Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- MFSLXXBSVZASQO-UHFFFAOYSA-N tert-butyl N-(2-bromo-4-methyl-6-nitrophenyl)carbamate Chemical compound BrC1=C(C(=CC(=C1)C)[N+](=O)[O-])NC(OC(C)(C)C)=O MFSLXXBSVZASQO-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- BUDSEUCTNFGKQN-UHFFFAOYSA-N tert-butyl-[[3-methoxy-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-6-yl]methoxy]-dimethylsilane Chemical compound [Si](C)(C)(C(C)(C)C)OCC1=CC(=C2N=CC(=NC2=C1)OC)B1OC(C(O1)(C)C)(C)C BUDSEUCTNFGKQN-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006092 tetrahydro-1,1-dioxothienyl group Chemical group 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000003856 thrombin receptor antagonist Substances 0.000 description 1
- 108010063955 thrombin receptor peptide (42-47) Proteins 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- HJOAXCLZLHDZDX-UHFFFAOYSA-N tris(1,2,2-trifluoroethenyl) borate Chemical compound FC(F)=C(F)OB(OC(F)=C(F)F)OC(F)=C(F)F HJOAXCLZLHDZDX-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362121P | 2016-07-14 | 2016-07-14 | |
| PCT/US2017/041880 WO2018013776A1 (en) | 2016-07-14 | 2017-07-13 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2823127T3 true ES2823127T3 (es) | 2021-05-06 |
Family
ID=59384259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17742926T Active ES2823127T3 (es) | 2016-07-14 | 2017-07-13 | Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20190315774A1 (OSRAM) |
| EP (1) | EP3484894B1 (OSRAM) |
| JP (1) | JP6903732B2 (OSRAM) |
| KR (1) | KR102468661B1 (OSRAM) |
| CN (1) | CN109689664B (OSRAM) |
| ES (1) | ES2823127T3 (OSRAM) |
| WO (1) | WO2018013776A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3484874B1 (en) | 2016-07-14 | 2020-04-29 | Bristol-Myers Squibb Company | Monocyclic heteroaryl substituted compounds |
| EP3484881B1 (en) | 2016-07-14 | 2020-04-29 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| JP7058256B2 (ja) | 2016-07-14 | 2022-04-21 | ブリストル－マイヤーズ スクイブ カンパニー | 二環式ヘテロアリール置換化合物 |
| CN111440146B (zh) * | 2020-05-15 | 2022-10-21 | 中国药科大学 | 一种具有par4拮抗活性的苯并三嗪类化合物及其应用 |
| CN117285527A (zh) * | 2023-09-25 | 2023-12-26 | 中国药科大学 | 一种噌啉类par4拮抗剂及其医药应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1164459A (en) * | 1980-11-11 | 1984-03-27 | Yung-Hsiung Yang | Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives |
| TW279162B (OSRAM) * | 1991-09-26 | 1996-06-21 | Mitsubishi Chem Corp | |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US6166041A (en) | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
| US6387942B2 (en) * | 2000-06-19 | 2002-05-14 | Yung Shin Pharmaceutical Ind. Co. Ltd | Method of treating disorders related to protease-activated receptors-induced cell activation |
| EP1348701A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors |
| US7511145B2 (en) | 2003-08-01 | 2009-03-31 | Genelabs Technologies, Inc. | Bicyclic heteroaryl derivatives |
| WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
| JP2008508314A (ja) | 2004-07-28 | 2008-03-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物 |
| AU2006204917A1 (en) | 2005-01-14 | 2006-07-20 | Smithkline Beecham Corporation | Indole derivatives for treating viral infections |
| WO2007149395A2 (en) | 2006-06-20 | 2007-12-27 | Amphora Discovery Corporation | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer |
| BRPI0713946A2 (pt) | 2006-06-29 | 2012-12-04 | Hoffmann La Roche | compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr, e uso dos compostos |
| WO2008073451A2 (en) | 2006-12-11 | 2008-06-19 | Sirtris Pharmaceuticals, Inc. | Benzoimidazole derivatives as sirtuin (sir) modulating compounds |
| EP2227770A4 (en) | 2007-11-30 | 2011-11-09 | Glaxosmithkline Llc | PROLYLHYDROXYLASEINHIBITOREN |
| CA2723135A1 (en) | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quenolines and related analogs as sirtuin modulators |
| EP2282995B1 (en) | 2008-05-23 | 2015-08-26 | Novartis AG | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| AU2009274023A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| US20130072473A1 (en) | 2011-05-09 | 2013-03-21 | Proteostasis Therapeutics, Inc. | Compounds for treating protein folding disorders |
| TW201348226A (zh) | 2012-02-28 | 2013-12-01 | Amgen Inc | 作為ｐｉｍ抑制劑之醯胺 |
| WO2013163241A1 (en) * | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| JP6073464B2 (ja) | 2012-04-26 | 2017-02-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピラジン誘導体 |
| BR112014026493A2 (pt) | 2012-04-26 | 2017-06-27 | Bristol Myers Squibb Co | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta |
| US9873670B2 (en) * | 2013-11-22 | 2018-01-23 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| US9617279B1 (en) | 2014-06-24 | 2017-04-11 | Bristol-Myers Squibb Company | Imidazooxadiazole compounds |
| US9598419B1 (en) | 2014-06-24 | 2017-03-21 | Universite De Montreal | Imidazotriazine and imidazodiazine compounds |
| EP3262052A1 (en) | 2015-02-26 | 2018-01-03 | Bristol-Myers Squibb Company | Benzothiazole and benzothiophne compounds |
| EP3262053B1 (en) | 2015-02-26 | 2022-10-05 | Université de Montréal | Imidazothiadiazole compounds as par4-inhibitors |
| EP3328839A1 (en) | 2015-07-30 | 2018-06-06 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| EP3484881B1 (en) | 2016-07-14 | 2020-04-29 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| JP7058256B2 (ja) * | 2016-07-14 | 2022-04-21 | ブリストル－マイヤーズ スクイブ カンパニー | 二環式ヘテロアリール置換化合物 |
| EP3484874B1 (en) | 2016-07-14 | 2020-04-29 | Bristol-Myers Squibb Company | Monocyclic heteroaryl substituted compounds |
-
2017
- 2017-07-13 US US16/317,258 patent/US20190315774A1/en not_active Abandoned
- 2017-07-13 WO PCT/US2017/041880 patent/WO2018013776A1/en not_active Ceased
- 2017-07-13 JP JP2019501630A patent/JP6903732B2/ja active Active
- 2017-07-13 EP EP17742926.3A patent/EP3484894B1/en active Active
- 2017-07-13 KR KR1020197004282A patent/KR102468661B1/ko active Active
- 2017-07-13 ES ES17742926T patent/ES2823127T3/es active Active
- 2017-07-13 CN CN201780056459.5A patent/CN109689664B/zh active Active
-
2021
- 2021-01-06 US US17/142,288 patent/US11932658B2/en active Active
-
2023
- 2023-12-06 US US18/530,405 patent/US20240309019A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190315774A1 (en) | 2019-10-17 |
| JP6903732B2 (ja) | 2021-07-14 |
| KR102468661B1 (ko) | 2022-11-17 |
| EP3484894B1 (en) | 2020-08-19 |
| EP3484894A1 (en) | 2019-05-22 |
| KR20190026906A (ko) | 2019-03-13 |
| US20240309019A1 (en) | 2024-09-19 |
| CN109689664A (zh) | 2019-04-26 |
| CN109689664B (zh) | 2022-04-15 |
| US20210188877A1 (en) | 2021-06-24 |
| WO2018013776A1 (en) | 2018-01-18 |
| JP2019524732A (ja) | 2019-09-05 |
| US11932658B2 (en) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12060347B2 (en) | Bicyclic heteroaryl substituted compounds | |
| AU2020343671C1 (en) | RIP1 inhibitory compounds and methods for making and using the same | |
| US11932658B2 (en) | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | |
| US10730868B2 (en) | Bicyclic heteroaryl substituted compounds | |
| EP4055021B1 (en) | Heterocyclic rip1 inhibitory compounds | |
| CA3257445A1 (en) | Oxazepine aza-tetracycline compounds and their uses | |
| ES2924371T3 (es) | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa | |
| EA025520B1 (ru) | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| KR20160098392A (ko) | Nrf2 조절제 | |
| CN109689642B (zh) | 经单环杂芳基取代的化合物 | |
| CN112409378A (zh) | 三环pi3k抑制剂化合物及其使用方法 | |
| US20250230138A1 (en) | Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications | |
| US20220315597A1 (en) | Tricyclic compounds and their use | |
| CA3162281A1 (en) | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | |
| WO2022166796A1 (zh) | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 | |
| NZ623098A (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. |